Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.

Iovino, Lorenzo; Shadman, Mazyar

Iovino, Lorenzo; Shadman, Mazyar.

Affiliation

Iovino L; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Shadman M; UO Ematologia, Università degli Studi di Pisa, Pisa, Italy.

Curr Treat Options Oncol ; 21(4): 24, 2020 03 13.

Article in En | MEDLINE | ID: mdl-32170458

Subject(s)

Leukemia, Lymphocytic, Chronic, B-Cell/therapy; Biomarkers, Tumor; Clinical Decision-Making; Combined Modality Therapy/adverse effects; Combined Modality Therapy/methods; Disease Management; Disease Susceptibility; Genetic Variation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis; Leukemia, Lymphocytic, Chronic, B-Cell/etiology; Leukemia, Lymphocytic, Chronic, B-Cell/mortality; Neoplasm Grading; Neoplasm Staging; Prognosis; Time-to-Treatment; Treatment Outcome

Key words

Acalabrutinib; CLL; Duvelisib; Ibrutinib; Idelalisib; SLL; Treatment; Venetoclax

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies Limits: Humans Language: En Journal: Curr Treat Options Oncol Year: 2020 Document type: Article

Fulltext

XML

PubMed Links

Search on Google